Prakhar Verma is a managing director in the firm’s strategic advisory practice, with ~15 years of experience in the biopharmaceuticals sector. He is based in Menlo Park.
Mr. Verma advises biotechnology corporates on financing, business development and licensing, and M&A topics. His experience on financing spans equity, equity-linked, debt and royalty financing, and he has represented biotech companies in raising ~$3B in equity proceeds over his career. Notable strategic transactions include advising on the Theravance Biopharma sale of Trelegy royalty interests to Royalty Pharma, and Gilead Science’s acquisition of Forty Seven.
Prior to joining Evercore in 2021, Mr. Verma was an investment banker at Citigroup. Earlier in his career, he was in sell-side biotechnology equity research, including as a vice president on the biotech equity research team at Stifel. He also was a healthcare consultant at Prescient Healthcare Group.
Mr. Verma holds a Ph.D. in biochemistry and structural biology from Stony Brook University, New York.